Sanaa: India has approved a dengue vaccine developed by Japan's Takeda Pharmaceutical, according to a statement from the company Monday. The approval of QDENGA marks the first dengue vaccine approved in India for use in individuals aged 4 to 60 years.

According to Anadolu Agency, Takeda expressed pride in their dengue vaccine being approved by India's Central Drugs Standard Control Organization (CDSCO), marking a significant milestone as the first dengue vaccine approval in India. The company emphasized the importance of this development at a time when reported dengue cases are increasing globally, with transmission patterns becoming unpredictable.

Takeda noted that as one of the world's largest dengue-endemic countries, India bears a significant portion of the global dengue burden. This approval is seen as an important advancement in enhancing dengue prevention efforts for communities most affected by the disease.

India records a large number of dengue cases annually. Official records indicate that the South Asian nation recorded 121,824 cases and 131 deaths last year. Dengue, caused by four related viruses and spread by Aedes mosquitoes, can lead to fever, severe pain, and in some cases, death.